A glaucoma diagnosis means committing to lifelong treatment and monitoring. The condition is manageable — and vision can be preserved — but only with consistent treatment and regular specialist review. This guide answers the key medical aid questions.
Does My Medical Aid Have to Cover This?
Yes. Glaucoma is a CDL condition. Prescribed eye drops for IOP reduction must be funded from the CDL benefit once registered. Acute angle-closure glaucoma — a sudden, severe rise in IOP with associated symptoms — is a PMB emergency requiring immediate treatment.
Register for CDL Immediately
Contact the scheme's chronic disease department with:
- Ophthalmologist's or optometrist's letter confirming the diagnosis (ICD-10: H40)
- Supporting diagnostic evidence — visual field test report and/or OCT report confirming optic nerve damage or glaucomatous field loss
- CDL registration form
Once registered, prescribed eye drops are funded from the CDL benefit — not your medical savings account. For a lifelong condition requiring daily drops, this is the single most important administrative step you can take.
Starting Eye Drops: What to Expect
Most patients with open-angle glaucoma are initially started on a prostaglandin analogue eye drop — typically latanoprost, bimatoprost, or travoprost. These are once-daily drops with excellent IOP-lowering efficacy and a good side-effect profile. Monthly cost on CDL formulary: approximately R300–R450 for prostaglandin analogues.
The most important thing to understand about glaucoma drops is that they work best when used exactly as prescribed, at the same time each day. Irregular adherence allows IOP spikes that cause incremental optic nerve damage. Each unit of nerve damage is permanent and cumulative.
If the first-line drop is insufficient to control IOP (confirmed by tonometry at follow-up), your ophthalmologist will add a second agent (timolol, brimonidine, or a combination preparation). Combination preparations with two agents in one bottle are preferred for adherence when two drugs are required.
Monitoring: The Most Important Investment
Glaucoma management is not just about drops — it is equally about monitoring the optic nerve and visual field over time to ensure the current treatment is working. The key monitoring tests:
Visual field testing (automated perimetry): Maps peripheral vision for losses characteristic of glaucoma. Done every 6–12 months in stable disease; more frequently if there is evidence of progression. Cost: R400–R900 per test.
OCT (optical coherence tomography) of the optic nerve: Structural imaging that detects retinal nerve fibre layer thinning — an early sign of progression, often before visual field loss is measurable. Typically annually for stable glaucoma. Cost: R800–R1,500.
Intraocular pressure measurement (tonometry): Monitored at every ophthalmology appointment.
Confirm with your scheme how visual field testing and OCT are covered. Some plans fund these as part of the ophthalmology specialist consultation; others have separate diagnostic imaging benefit limits. Budget for at least one of each per year.
SLT Laser Treatment: Should You Consider It?
Selective laser trabeculoplasty (SLT) is increasingly recommended as a primary or adjunct treatment for open-angle glaucoma. Evidence from the LiGHT trial (UK) showed that SLT is as effective as eye drops as initial therapy in the majority of patients and delays or avoids the need for drops. It can also be used alongside drops if drops alone are not achieving target IOP.
SLT is a painless, non-invasive outpatient procedure (no incision). It takes approximately 10–15 minutes. Results typically last 2–5 years; the procedure can be repeated. Discuss with your ophthalmologist whether SLT is appropriate for your case.
Cost: R5,000–R15,000 per session. Confirm pre-authorisation with your scheme in advance.
When Surgery Is Discussed
If maximum tolerated medical therapy (drops) and laser treatment have not achieved adequate IOP control, or if the disease is rapidly progressing, your ophthalmologist may recommend trabeculectomy. This is the gold-standard surgical procedure for significant IOP reduction.
Financial preparation: - Request pre-authorisation explicitly for the procedure and confirm whether it falls under the in-hospital benefit or a surgical benefit - Ask for the ophthalmologist's fee and compare it to the scheme rate — confirm the shortfall - Arrange gap cover if not already in place (specialist shortfall on ophthalmological surgery: R15,000–R50,000) - Ask about post-operative monitoring requirements — trabeculectomy requires frequent follow-up visits in the first month
Practical Checklist
| Action | Priority |
|---|---|
| Register for CDL (ICD-10: H40) | Immediate |
| Confirm prescribed eye drops are CDL-funded | This week |
| Schedule follow-up appointment at 6–8 weeks after starting treatment | Per ophthalmologist |
| Confirm visual field and OCT coverage with scheme | This week |
| Ask ophthalmologist about SLT if drops are not achieving target IOP | At next appointment |
| Pre-authorise any laser or surgical procedure before booking | Before any procedure |
Adherence Resources
The biggest threat to glaucoma outcomes is not inadequate treatment — it is irregular adherence to prescribed drops. Set a phone alarm for the same time daily. Ask a family member to provide a reminder. Many ophthalmologists' practices have nurses who can provide adherence support calls.
Talk to Eldon
Get help understanding your plan options →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
Understanding the Long-Term Nature of Glaucoma Management
Glaucoma is a lifelong condition. Treatment does not cure it — it arrests progression. This means the goal shifts from recovery to preservation, and the medical aid relationship is also lifelong.
Key long-term realities to plan for:
- You will need eye drops indefinitely, and the drops will change over time if IOP control is insufficient or if tolerance to a medication diminishes.
- Monitoring (OCT, visual field tests) is not optional — it is the only way to know whether treatment is working. Patients who skip monitoring may not know progression has occurred until the damage is severe.
- Surgical intervention probability increases with disease duration. Patients diagnosed in their 50s with moderate glaucoma have a meaningful lifetime chance of requiring SLT or trabeculectomy before age 70. Plan for this.
When reviewing plan benefits at annual selection time, specifically assess: - Ophthalmological specialist benefit - Diagnostic imaging benefit (OCT) - Outpatient specialist investigation benefit (visual field testing) - Surgical benefit limit for ophthalmological procedures
Your needs will evolve over years. AURA's advisory engine re-evaluates your plan fit as your condition profile changes.